A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

This study has 2 parts: Dose Escalation (part 1) and Dose Expansion (part 2) which are
conducted in 3 phases: Screening Phase (up to 28 days prior to first dose of study drug and
includes procedures like electrocardiogram [ECG], serum pregnancy test), Treatment phase
(continues until the completion of the End-of-Treatment Visit [30 days after last dose of
study drug]) and Post-treatment follow-up phase (continues until the participant has died, is
lost to follow-up, or has withdrawn consent or the study ends). In follow-up, participants
will continue to be monitored for survival status and subsequent cancer-related therapies
until the end of study. Additional bio-markers will be assessed, in an optional sub-study, to
define the impact of JNJ-64457107 on innate and adaptive immune responses in tumors. Safety
will be monitored throughout the study by Safety Evaluation Team (SET).

Inclusion Criteria:

- Part 1: advanced stage solid tumors; Part 2: non-small cell lung cancer (NSCLC),
pancreatic cancer and cutaneous melanoma

- Eastern cooperative oncology group (ECOG) performance score of 0 or 1

- Adequate organ function as defined in the protocol

- A woman of childbearing potential must have a negative highly sensitive serum
(beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at Screening and a
negative urine pregnancy test prior to the first dose of study drug

- During the study and for at least 120 days after receiving the last dose of study
drug, in addition to the highly effective method of contraception, a man who is
sexually active with a woman of childbearing potential must agree to use a barrier
method of contraception (example [eg.], condom with spermicidal
foam/gel/film/cream/suppository), or who is sexually active with a woman who is
pregnant must use a condom

Exclusion Criteria:

- Malignancy other than the disease under study within 2 years before screening
(exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ
of the cervix, or malignancy that in the opinion of the investigator, with concurrence
with the sponsor's medical monitor, is considered cured with minimal risk of
recurrence)

- Symptomatic brain metastases; asymptomatic brain metastases are allowed provided that
they have been treated, have been stable for greater than (>) 6 weeks as documented by
radiographic imaging, and do not require prolonged (>14 days) systemic corticosteroid
therapy

- Treatment with any local or systemic anti-neoplastic therapy or investigational
anticancer agent within 14 days or 4 half-lives, whichever is longer, up to a maximum
wash-out period of 28 days prior to the initiation of study drug administration

- Toxicities from previous anti-cancer therapies have not resolved to baseline levels or
to Grade 1 or less except for alopecia and peripheral neuropathy

- Major surgery (eg., requiring general anesthesia) within 3 weeks before screening, or
will not have fully recovered from surgery, or has surgery planned during the time the
subject is expected to participate in the study